



Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment

PITTSBURGH, Aug. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. The preparation is the first generic version of Sanofi Aventis' BenzaClin® to be approved by the U.S. Food and Drug Administration (FDA).

On Aug. 11, Dow received FDA approval for its Abbreviated New Drug Application (ANDA) for Clindamycin 1% and Benzoyl Peroxide 5% Gel, a prescription-strength topical antibiotic used to treat acne. According to IMS Health, BenzaClin had total U.S. sales of approximately \$221 million for the 12 months ending June 30.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; operates a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

Media, Michael Laffin, +1-724-514-1968, or Investors, Dan Crookshank, +1-724-514-1813, both of Mylan Inc.